Posted by Michael Wonder on 14 Oct 2016
NICE publishes draft guidance on the use of Opdivo by patients with NSCLC
14 October 2016 - NICE has published draft guidance on the use of Opdivo (nivolumab) by patients with lung cancer.
Once again, NICE has said 'non' & 'non' to the use of nivolumab in patients with squamous cell or non-squamous cell lung cancer (NSCLC). NICE has said that it is open to the possibility of a listing of Opdivo in the Cancer Drugs Fund for use by patients with NSCLC.
This draft decision comes just days after the SMC recommended the use of nivolumab by patients with non-squamous cell lung cancer.
